It has been clearly established that protein kinase C (PKC) isoforms have a role in several processes in Alzheimer’s disease (AD). The proposed study is a medicinal chemistry project which aims at designing, synthesizing and biological evaluation of compounds targeted to the C1 domain of PKC. We have previously synthesized more than 200 compounds and have carried out SAR-studies which have confirmed the important functional groups indispensable for binding to the C1 domain. These compounds will be examined for their activity in AD-related cellular functions. With this proposed project we expect to develop new PKC-targeted drug candidates that could be used to treat PKC-mediated diseases such as AD.
|Effective start/end date||01/01/2010 → 31/12/2011|
- Päivikki ja Sakari Sohlbergin säätiö